64 related articles for article (PubMed ID: 9426338)
1. Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas.
Palumbo R; Palmeri S; Antimi M; Gatti C; Raffo P; Villani G; Toma S
Ann Oncol; 1997 Nov; 8(11):1159-62. PubMed ID: 9426338
[TBL] [Abstract][Full Text] [Related]
2. Ifosfamide-based combination chemotherapy in advanced soft-tissue sarcoma: a practice guideline.
Verma S; Younus J; Stys-Norman D; Haynes AE; Blackstein M
Curr Oncol; 2007 Aug; 14(4):144-8. PubMed ID: 17710206
[TBL] [Abstract][Full Text] [Related]
3. Prospective, Multicenter Phase II Trial of Non-Pegylated Liposomal Doxorubicin Combined with Ifosfamide in First-Line Treatment of Advanced/Metastatic Soft Tissue Sarcomas.
Buonadonna A; Scalone S; Lombardi D; Fumagalli A; Guglielmi A; Lestuzzi C; Polesel J; Canzonieri V; Lamon S; Giovanis P; Gagno S; Corona G; Mascarin M; Belluco C; De Paoli A; Fasola G; Puglisi F; Miolo G
Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894403
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis B Reactivation After Ifosfamide Therapy for Retroperitoneal Sarcoma.
Chhibar P; Zhu Z; Cheedella NK; Chaudhry R; Wang JC
Am J Case Rep; 2016 Jun; 17():371-4. PubMed ID: 27246626
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of second and third lines of treatment in advanced soft tissue sarcomas: a real-world study.
Gutierrez-Sainz L; Martinez-Fdez S; Pedregosa-Barbas J; Peña J; Alameda M; Viñal D; Villamayor J; Martinez-Recio S; Perez-Wert P; Pertejo-Fernandez A; Gallego A; Martinez-Marin V; Zamora P; Espinosa E; Mendiola M; Feliu J; Redondo A
Clin Transl Oncol; 2023 Dec; 25(12):3519-3526. PubMed ID: 37329429
[TBL] [Abstract][Full Text] [Related]
6. A phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcomas: a study of the Mayo phase 2 consortium (P2C).
Okuno S; Bailey H; Mahoney MR; Adkins D; Maples W; Fitch T; Ettinger D; Erlichman C; Sarkaria JN
Cancer; 2011 Aug; 117(15):3468-75. PubMed ID: 21287536
[TBL] [Abstract][Full Text] [Related]
7. Characteristics and Treatment Patterns of Patients with Advanced Soft Tissue Sarcoma in Korea.
Kim HS; Nam CM; Jang SY; Choi SK; Han M; Kim S; Moneta MV; Lee SY; Cho JM; Novick D; Rha SY
Cancer Res Treat; 2019 Oct; 51(4):1380-1391. PubMed ID: 30776883
[TBL] [Abstract][Full Text] [Related]
8. Renal toxicity of ifosfamide in children with cancer: an exploratory study integrating aldehyde dehydrogenase enzymatic activity data and a wide-array urinary metabolomics approach.
Febvey-Combes O; Guitton J; Marec-Berard P; Faure-Conter C; Blanc E; Chabaud S; Conjard-Duplany A; Schell M; Derain Dubourg L
BMC Pediatr; 2024 Mar; 24(1):196. PubMed ID: 38504218
[TBL] [Abstract][Full Text] [Related]
9. Priorities and preferences of advanced soft tissue sarcoma patients starting palliative chemotherapy: baseline results from the HOLISTIC study.
Younger E; Jones RL; den Hollander D; Soomers VLMN; Desar IME; Benson C; Young RJ; Oosten AW; de Haan JJ; Miah A; Zaidi S; Gelderblom H; Steeghs N; Husson O; van der Graaf WTA
ESMO Open; 2021 Oct; 6(5):100258. PubMed ID: 34509803
[TBL] [Abstract][Full Text] [Related]
10. UK guidelines for the management of soft tissue sarcomas.
Hayes AJ; Nixon IF; Strauss DC; Seddon BM; Desai A; Benson C; Judson IR; Dangoor A
Br J Cancer; 2024 May; ():. PubMed ID: 38734790
[TBL] [Abstract][Full Text] [Related]
11. Pediatric Non-Rhabdomyosarcoma Soft Tissue Sarcomas: Standard of Care and Treatment Recommendations from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG).
Ferrari A; Brennan B; Casanova M; Corradini N; Berlanga P; Schoot RA; Ramirez-Villar GL; Safwat A; Guillen Burrieza G; Dall'Igna P; Alaggio R; Lyngsie Hjalgrim L; Gatz SA; Orbach D; van Noesel MM
Cancer Manag Res; 2022; 14():2885-2902. PubMed ID: 36176694
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of dacarbazine given with modern prophylactic anti-emetics and growth factor support to patients with metastatic, resistant soft tissue, and bone sarcoma.
Van Tine BA; Weiss MC; Hirbe AC; Oppelt PJ; Abaricia S; Trinkaus K; Luo J; Berry S; Ruff T; Callahan C; Toensikoetter J; Ley J; Siegel MJ; Dehdashti F; Siegel BA; Adkins DR
Rare Tumors; 2021; 13():20363613211052498. PubMed ID: 34646430
[TBL] [Abstract][Full Text] [Related]
13. Continuous 14 Day Infusional Ifosfamide for Management of Soft-Tissue and Bone Sarcoma: A Single Centre Retrospective Cohort Analysis.
Carter TJ; Milic M; McDerra J; McTiernan A; Ahmed M; Karavasilis V; Michelagnoli M; Windsor R; Seddon B; Whelan J; Dileo P; Strauss SJ
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33212978
[TBL] [Abstract][Full Text] [Related]
14. A sub-Saharan African experience in the surgical management of soft tissue sarcomas in an oncology unit in: a retrospective cohort study.
Ayandipo OO; Afuwape OO; Soneye OY; Orunmuyi AT; Obajimi GO
Pan Afr Med J; 2019; 33():207. PubMed ID: 31692722
[TBL] [Abstract][Full Text] [Related]
15. Managing sarcoma: where have we come from and where are we going?
Bleloch JS; Ballim RD; Kimani S; Parkes J; Panieri E; Willmer T; Prince S
Ther Adv Med Oncol; 2017 Oct; 9(10):637-659. PubMed ID: 28974986
[TBL] [Abstract][Full Text] [Related]
16. High-Dose Ifosfamide Chemotherapy in a Series of Patients Affected by Myxoid Liposarcoma.
Colia V; Fumagalli E; Provenzano S; Bertulli R; Stacchiotti S; Morosi C; Collini P; Gronchi A; Casali PG; Sanfilippo R
Sarcoma; 2017; 2017():3739159. PubMed ID: 28947876
[TBL] [Abstract][Full Text] [Related]
17. Activity of anthracycline- and ifosfamide-based chemotherapy in a series of patients affected by advanced myxofibrosarcoma.
Colia V; Fiore M; Provenzano S; Fumagalli E; Bertulli R; Morosi C; Dei Tos AP; Barisella M; Gronchi A; Casali PG; Sanfilippo R
Clin Sarcoma Res; 2017; 7():16. PubMed ID: 28852467
[TBL] [Abstract][Full Text] [Related]
18. Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations.
In GK; Hu JS; Tseng WW
Ther Adv Med Oncol; 2017 Aug; 9(8):533-550. PubMed ID: 28794805
[TBL] [Abstract][Full Text] [Related]
19. UK guidelines for the management of soft tissue sarcomas.
Dangoor A; Seddon B; Gerrand C; Grimer R; Whelan J; Judson I
Clin Sarcoma Res; 2016; 6():20. PubMed ID: 27891213
[TBL] [Abstract][Full Text] [Related]
20. High-dose continuous-infusion ifosfamide in advanced well-differentiated/dedifferentiated liposarcoma.
Sanfilippo R; Bertulli R; Marrari A; Fumagalli E; Pilotti S; Morosi C; Messina A; Dei Tos AP; Gronchi A; Casali PG
Clin Sarcoma Res; 2014; 4(1):16. PubMed ID: 25628856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
